Mycophenolic acid pharmacokinetics in pediatric liver transplant recipients

Liver Transplantation

Volumn 9, Issue 4, 2003, Pages 383-388

  Aw, Marion M ^a   Brown, Nigel W ^a   Itsuka, Toshi ^a   Gonde, Christopher E ^a   Adams, Jemimah E ^a   Heaton, Nigel D ^a   Tredger, J Michael ^a   Mieli Vergani, Giorgina ^a   Dhawan, Anil ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; CALCULATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIARRHEA; DRUG BLOOD LEVEL; ENZYME IMMUNOASSAY; FEMALE; HUMAN; LEUKOPENIA; LIVER TRANSPLANTATION; MALE; PRIORITY JOURNAL; RECIPIENT;

EID: 0037387864     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2003.50022     Document Type: Article

References (28)

1. The European Mycophenolate Mofetil Co-operative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995;1:1321-1325.
2. Sollenger HW for the US Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients, the US Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995;60:225-232.
3. Eugui EM, Allison AC. Immunosuppressive activity of mycophenolate mofetil. Ann NY Acad Sci 1993;685:309-329.
4. Sterneck M, Fisher L, Gahlemann C, Gundlach M, Rogiers X, Broelsch C. Mycophenolate mofetil for prevention of liver allograft rejection: Initial results of a controlled clinical trial. Ann Transplant 2000;5:43-46.
5. Herbert MF, Ascher NL, Lake JR, Emond J, Nikolai B, Linna TJ, Roberts JP. Four-year follow-up of mycophenolate mofetil for graft rescue in liver allograft recipients. Transplantation 1999;67:707-712.
6. The Mycophenolate Mofetil Renal Refractory Rejection Study Group. Rescue therapy with mycophenolate mofetil. Clin Transplant 1996;10:131-135.
7. Chardot C, Nicoluzzi JE, Janssen M, Sokal E, Lerut J, Otte JB, Reding R. Use of mycophenolate mofetil as rescue therapy after pediatric liver transplantation. Transplantation 2001;71;224-229.
8. Bullingham RES, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998;34: 429-455.
9. Weber LT, Shipkova M, Lamersdorf T, Shipkova M, Niedmann P, Oellerich M, et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. J Am Soc Nephrol 1998;9: 1511-1520.
10. Aw MM, Samaroo B, Baker AJ, Verma A, Rela M, Heaton ND, et al. Calcineurin-inhibitor related nephrotoxicity - Reversibility in paediatric liver transplant recipients. Transplantation 2001;72:746-749.
11. Renz JF, Lightdale J, Mudge C, Bacchetti P, Watson J, Ascher ND, et al. Mycophenolate mofetil, microemulsion cyclosporine, and prednisone as primary immunosuppression for pediatric liver transplant recipients. Liver Transpl Surg 1999;5:136-143.
12. Filler G, Zimmering M, Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol 2000;14:100-104.
13. Vidal E, Cantarell C, Capdevila L, Monforte V, Roman A, Pou L. Mycophenolate mofetil pharmacokinetics in transplant patients receiving cyclosporine or tacrolimus in combination therapy. Pharmacol Toxicol 2000;87:182-184.
14. Bullingham RES, Nicolls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): A short review. Transplant Proc 1996;28:925-929.
15. Van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, De Fijter JW, Squifflet JP, et al. A randomised double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999;68:261-266.
16. Mourad M, Malaise J, Chaib Eddour D, De Meyer D, Konig J, Schepers R, et al. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil. Clin Chem 2001;47:88-94.
17. Shaw LM, Korecka M, DeNofrio D, Brayman KL. Pharmacokinetic, pharmacodynamic and outcome investigations as the basis for mycophenolic acid therapeutic drug monitoring in renal and heart transplant patients. Clin Biochem 2001;34:17-22.
18. Shaw LM, Nicholls A, Hale M, Armstrong VW, Ollerich M, Yatscoff R, et al. Therapeutic monitoring of mycophenolic acid. A consensus panel report. Clin Biochem 1998;31:317-322.
19. Weber LT, Lamersdorf T, Shipkova M, Niedmann PD, Wiesel M, Zimmerhackl LB, et al. Area under the plasma concentration time curve for total but not free mycophenolic acid increases in the stable phase after renal transplantation: A longitudinal study in pediatric patients. Ther Drug Monit 1999;21:498-506.
20. Shah J, Bullingham R, Rice P, Tsina I, Swan S, Halstenson C. Pharmacokinetics of oral mycophenolate mofetil and metabolites in renally impaired patients [abstract]. Clin Pharmacol Ther 1995;57:149A.
21. Brunet M, Martorell J, Oppenheimer F, Vilardell J, Millan O, Carrillo M, et al. Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil. Transpl Int 2000; 13(suppl 1):S301-S305.
22. Filler G, Mai I. Limited sampling strategy for mycophenolic acid area under the curve. Ther Drug Monit 2000;22:169-173.
23. Gregoor PJ, de Sevaux RG, Hene RJ, Hesse CJ, Hilbrands LB, Vos P, et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation 1999;68: 1603-1606.
24. Gregoor PJ, van Gelder T, Hesse CJ, van der Mast BJ, van Besouw NM, Weimar W. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: A cross-sectional study. Nephrol Dial Transplant 1999;14:706-708.
25. Hubner GI, Eismann R, Sziegoleit W. Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients. Ther Drug Monit 1999;21:536-539.
26. Zucker K, Tsaroucha A, Olson L, Esquenazi V, Tzakis A, Miller J. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation. Ther Drug Monit 1999;21:35-43.
27. van Gelder T, Klupp J, Barten M, Christians U, Morris RE. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001;23:119-128.
28. Brown N, Aw MM, Mieli-Vergani G, Dhawan A, Tredger JM. Mycophenolic acid and mycophenolic acid glucuronide pharmacokinetics in pediatric liver transplant recipients: Effect of cyclosporine and tacrolimus co-medication. Ther Drug Monit 2002; 24:598-606.